-
The Arylamine N-Acetyltransferases as Therapeutic Targets in Metabolic Diseases Associated with Mitochondrial Dysfunction Pharmacol. Rev. (IF 21.1) Pub Date : 2024-03-01 Chandra Choudhury, Melinder K. Gill, Courtney E. McAleese, Neville J. Butcher, Shyuan T. Ngo, Frederik J. Steyn, Rodney F. Minchin, Michael Gottesman
In humans, there are two arylamine N-acetyltransferase genes that encode functional enzymes (NAT1 and NAT2) as well as one pseudogene, all of which are located together on chromosome 8. Although they were first identified by their role in the acetylation of drugs and other xenobiotics, recent studies have shown strong associations for both enzymes in a variety of diseases, including cancer, cardiovascular
-
The Role of G Protein-Coupled Receptors and Receptor Kinases in Pancreatic {beta}-Cell Function and Diabetes Pharmacol. Rev. (IF 21.1) Pub Date : 2024-02-13 Varney, M. J., Benovic, J. L.
Type 2 diabetes (T2D) mellitus has emerged as a major global health concern that has accelerated in recent years due to poor diet and lifestyle. Afflicted individuals have high blood glucose levels that stem from the inability of the pancreas to make enough insulin to meet demand. Although medication can help to maintain normal blood glucose levels in individuals with chronic disease, many of these
-
Protecting Human and Animal Health: The Road from Animal Models to New Approach Methods Pharmacol. Rev. (IF 21.1) Pub Date : 2024-02-13 Kaplan, B. L. F., Hoberman, A. M., Slikker, W., Smith, M. A., Corsini, E., Knudsen, T. B., Marty, M. S., Sobrian, S. K., Fitzpatrick, S. C., Ratner, M. H., Mendrick, D. L.
Animals and animal models have been invaluable for our current understanding of human and animal biology, including physiology, pharmacology, biochemistry, and disease pathology. However, there are increasing concerns with continued use of animals in basic biomedical, pharmacological, and regulatory research to provide safety assessments for drugs and chemicals. There are concerns that animals do not
-
Leveraging Lymphatic System Targeting in Systemic Lupus Erythematosus for Improved Clinical Outcomes Pharmacol. Rev. (IF 21.1) Pub Date : 2024-03-01 K.T. Babalola, M. Arora, R. Ganugula, S.K. Agarwal, C. Mohan, M.N.V. Ravi Kumar, Francesca Levi-Schaffer
The role of advanced drug delivery strategies in drug repositioning and minimizing drug attrition rates, when applied early in drug discovery, is poised to increase the translational impact of various therapeutic strategies in disease prevention and treatment. In this context, drug delivery to the lymphatic system is gaining prominence not only to improve the systemic bioavailability of various pharmaceutical
-
Emergence of Extracellular Vesicles as “Liquid Biopsy” for Neurological Disorders: Boom or Bust Pharmacol. Rev. (IF 21.1) Pub Date : 2024-03-01 Ashish Kumar, Michael A. Nader, Gagan Deep, Andrew Baker
-
The SLC6A15–SLC6A20 Neutral Amino Acid Transporter Subfamily: Functions, Diseases, and Their Therapeutic Relevance Pharmacol. Rev. (IF 21.1) Pub Date : 2024-01-01 Jędrzej Kukułowicz, Krzysztof Pietrzak-Lichwa, Klaudia Klimończyk, Nathalie Idlin, Marek Bajda, Habibeh Khoshbouei
-
Halogenated Antimicrobial Agents to Combat Drug-Resistant Pathogens Pharmacol. Rev. (IF 21.1) Pub Date : 2024-01-01 Olajide Sunday Faleye, Bharath Reddy Boya, Jin-Hyung Lee, Inho Choi, Jintae Lee, Clive Page
-
Targeting the Liver with Nucleic Acid Therapeutics for the Treatment of Systemic Diseases of Liver Origin Pharmacol. Rev. (IF 21.1) Pub Date : 2024-01-01 Anagha Gogate, Jordyn Belcourt, Milan Shah, Alicia Zongxun Wang, Alexis Frankel, Holly Kolmel, Matthew Chalon, Prajith Stephen, Aarush Kolli, Sherouk M. Tawfik, Jing Jin, Raman Bahal, Theodore P. Rasmussen, José E. Manautou, Xiao-bo Zhong, Grace Guo
-
Nonhormonal Male Contraceptive Development--Strategies for Progress Pharmacol. Rev. (IF 21.1) Pub Date : 2023-12-15 Nickels, L., Yan, W.
Despite the widely demonstrated public health benefits of contraception, limited contraceptive options are available for men, placing both the contraceptive burden and opportunity solely on women. This review outlines the need for an increased focus on male contraceptive development and highlights several related topics, including the perspectives of women and men on male contraceptives, historical
-
Regulation of Pain Perception by Microbiota in Parkinson Disease Pharmacol. Rev. (IF 21.1) Pub Date : 2024-01-01 Zulmary Manjarres, Margarita Calvo, Rodrigo Pacheco, Habibeh Khoshbouei
-
Pharmacological Reviews’75th Year Anniversary: Past and Future—Editorial Pharmacol. Rev. (IF 21.1) Pub Date : 2024-01-01 Lynette C. Daws
-
International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily—Update 2023 Pharmacol. Rev. (IF 21.1) Pub Date : 2023-11-01 Thomas P. Burris, Ian Mitchelle S. de Vera, Isabelle Cote, Colin A. Flaveny, Udayanga S. Wanninayake, Arindam Chatterjee, John K. Walker, Nickolas Steinauer, Jinsong Zhang, Laurel A. Coons, Kenneth S. Korach, Derek W. Cain, Anthony N. Hollenberg, Paul Webb, Douglas Forrest, Anton M. Jetten, Dean P. Edwards, Sandra L. Grimm, Sean Hartig, Carol A. Lange, Jennifer K. Richer, Carol A. Sartorius, Marc Tetel
The NR superfamily comprises 48 transcription factors in humans that control a plethora of gene network programs involved in a wide range of physiologic processes. This review will summarize and discuss recent progress in NR biology and drug development derived from integrating various approaches, including biophysical techniques, structural studies, and translational investigation. We also highlight
-
Targeting Epidermal Growth Factor Receptor for Cancer Treatment: Abolishing Both Kinase-Dependent and Kinase-Independent Functions of the Receptor Pharmacol. Rev. (IF 21.1) Pub Date : 2023-11-01 Yuesheng Zhang, Michael Gottesman
-
Lymphocyte Depleting and Modulating Therapies for Chronic Lung Allograft Dysfunction Pharmacol. Rev. (IF 21.1) Pub Date : 2023-11-01 Saskia Bos, Pauline Pradère, Hanne Beeckmans, Andrea Zajacova, Bart M. Vanaudenaerde, Andrew J. Fisher, Robin Vos, Clive Page
Chronic lung rejection, also called chronic lung allograft dysfunction (CLAD), remains the major hurdle limiting long-term survival after lung transplantation, and limited therapeutic options are available to slow the progressive decline in lung function. Most interventions are only temporarily effective in stabilizing the loss of or modestly improving lung function, with disease progression resuming
-
Therapeutic Potential of Targeting Prokineticin Receptors in Diseases Pharmacol. Rev. (IF 21.1) Pub Date : 2023-11-01 Martina Vincenzi, Amin Kremić, Appoline Jouve, Roberta Lattanzi, Rossella Miele, Mohamed Benharouga, Nadia Alfaidy, Stephanie Migrenne-Li, Anumantha G. Kanthasamy, Marimelia Porcionatto, Napoleone Ferrara, Igor V. Tetko, Laurent Désaubry, Canan G. Nebigil, Rhian Touyz
-
Effects of Medications on Heat Loss Capacity in Chronic Disease Patients: Health Implications Amidst Global Warming Pharmacol. Rev. (IF 21.1) Pub Date : 2023-11-01 Jericho Wee, Xiang Ren Tan, Samuel H. Gunther, Mohammed Ihsan, Melvin Khee Shing Leow, Doreen Su-Yin Tan, Johan G. Eriksson, Jason Kai Wei Lee, Lynette Daws
-
Optical Approaches for Investigating Neuromodulation and G Protein–Coupled Receptor Signaling Pharmacol. Rev. (IF 21.1) Pub Date : 2023-11-01 David J. Marcus, Michael R. Bruchas, Gunnar Schulte
-
Oxycodone: A Current Perspective on Its Pharmacology, Abuse, and Pharmacotherapeutic Developments Pharmacol. Rev. (IF 21.1) Pub Date : 2023-10-17 Barrett, J. E., Shekarabi, A., Inan, S.
Oxycodone, a semisynthetic derivative of naturally occurring thebaine, an opioid alkaloid, has been available for more than 100 years. Although thebaine cannot be used therapeutically due to the occurrence of convulsions at higher doses, it has been converted to a number of other widely used compounds that include naloxone, naltrexone, buprenorphine, and oxycodone. Despite the early identification
-
Extracellular Vesicle Heterogeneity and Its Impact for Regenerative Medicine Applications Pharmacol. Rev. (IF 21.1) Pub Date : 2023-08-14 van de Wakker, S. I., Meijers, F. M., Sluijter, J. P. G., Vader, P.
Extracellular vesicles (EVs) are cell-derived membrane-enclosed particles that are involved in physiologic and pathologic processes. EVs are increasingly being studied for therapeutic applications in the field of regenerative medicine. Therapeutic application of stem cell–derived EVs has shown great potential to stimulate tissue repair. However, the exact mechanisms through which they induce this effect
-
Hepatic Bile Formation: Developing a New Paradigm Pharmacol. Rev. (IF 21.1) Pub Date : 2023-08-14 Javitt, N. B.
In 1959, Ivar Sperber contrasted bile formation with that of urine and proposed that water flow into the canalicular conduit is in response to an osmotic, not a hydrostatic, gradient. Early attempts to support the hypothesis using a bile acid, sodium taurocholate, and the hormone secretin to stimulate bile flow led to conflicting data and a moratorium on attempts to further develop the initial proposal
-
The Myc Family and the Metastasis Suppressor NDRG1: Targeting Key Molecular Interactions with Innovative Therapeutics Pharmacol. Rev. (IF 21.1) Pub Date : 2023-08-14 Deng, Z., Richardson, D. R.
Cancer is a leading cause of death worldwide, resulting in ~10 million deaths in 2020. Major oncogenic effectors are the Myc proto-oncogene family, which consists of three members including c-Myc, N-Myc, and L-Myc. As a pertinent example of the role of the Myc family in tumorigenesis, amplification of MYCN in childhood neuroblastoma strongly correlates with poor patient prognosis. Complexes between
-
Paradoxes of Cellular SUMOylation Regulation: A Role of Biomolecular Condensates? Pharmacol. Rev. (IF 21.1) Pub Date : 2023-08-14 Cheng, X., Yang, W., Lin, W., Mei, F.
Protein SUMOylation is a major post-translational modification essential for maintaining cellular homeostasis. SUMOylation has long been associated with stress responses as a diverse array of cellular stress signals are known to trigger rapid alternations in global protein SUMOylation. In addition, while there are large families of ubiquitination enzymes, all small ubiquitin-like modifiers (SUMOs)
-
Pharmacological Regulation of Endoplasmic Reticulum Structure and Calcium Dynamics: Importance for Neurodegenerative Diseases Pharmacol. Rev. (IF 21.1) Pub Date : 2023-08-14 Parkkinen, I., Their, A., Asghar, M. Y., Sree, S., Jokitalo, E., Airavaara, M.
The endoplasmic reticulum (ER) is the largest organelle of the cell, composed of a continuous network of sheets and tubules, and is involved in protein, calcium (Ca2+), and lipid homeostasis. In neurons, the ER extends throughout the cell, both somal and axodendritic compartments, and is highly important for neuronal functions. A third of the proteome of a cell, secreted and membrane-bound proteins
-
Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years Pharmacol. Rev. (IF 21.1) Pub Date : 2023-08-14 Maccarrone, M., Di Marzo, V., Gertsch, J., Grether, U., Howlett, A. C., Hua, T., Makriyannis, A., Piomelli, D., Ueda, N., van der Stelt, M.
The cannabis derivative marijuana is the most widely used recreational drug in the Western world and is consumed by an estimated 83 million individuals (~3% of the world population). In recent years, there has been a marked transformation in society regarding the risk perception of cannabis, driven by its legalization and medical use in many states in the United States and worldwide. Compelling research
-
{beta}-Arrestins: Structure, Function, Physiology, and Pharmacological Perspectives Pharmacol. Rev. (IF 21.1) Pub Date : 2023-08-14 Wess, J., Oteng, A.-B., Rivera-Gonzalez, O., Gurevich, E. V., Gurevich, V. V.
The two β-arrestins, β-arrestin-1 and -2 (systematic names: arrestin-2 and -3, respectively), are multifunctional intracellular proteins that regulate the activity of a very large number of cellular signaling pathways and physiologic functions. The two proteins were discovered for their ability to disrupt signaling via G protein-coupled receptors (GPCRs) via binding to the activated receptors. However
-
ABCB1 and ABCG2 Regulation at the Blood-Brain Barrier: Potential New Targets to Improve Brain Drug Delivery Pharmacol. Rev. (IF 21.1) Pub Date : 2023-08-14 Schulz, J. A., Hartz, A. M. S., Bauer, B.
The drug efflux transporters ABCB1 and ABCG2 at the blood-brain barrier limit the delivery of drugs into the brain. Strategies to overcome ABCB1/ABCG2 have been largely unsuccessful, which poses a tremendous clinical problem to successfully treat central nervous system (CNS) diseases. Understanding basic transporter biology, including intracellular regulation mechanisms that control these transporters
-
Oxycodone: A Current Perspective on Its Pharmacology, Abuse, and Pharmacotherapeutic Developments. Pharmacol. Rev. (IF 21.1) Pub Date : 2023-06-15 James E Barrett,Aryan Shekarabi,Saadet Inan
Oxycodone, a semisynthetic derivative of naturally occurring thebaine, an opioid alkaloid, has been available for more than 100 years. Although thebaine cannot be used therapeutically due to the occurrence of convulsions at higher doses, it has been converted to a number of other widely used compounds that include naloxone, naltrexone, buprenorphine, and oxycodone. Despite the early identification
-
Pharmacogenomics: Driving Personalized Medicine Pharmacol. Rev. (IF 21.1) Pub Date : 2023-07-01 Wolfgang Sadee, Danxin Wang, Katherine Hartmann, Amanda Ewart Toland, Hyunyoung Jeong
-
Potassium Channels in Parkinson’s Disease: Potential Roles in Its Pathogenesis and Innovative Molecular Targets for Treatment Pharmacol. Rev. (IF 21.1) Pub Date : 2023-07-01 Xiaoyi Chen, Yunjiang Feng, Ronald J. Quinn, Dean L. Pountney, Des R. Richardson, George D. Mellick, Linlin Ma, Habibeh Khoshbouei
-
Advances in Nanozymes as a Paradigm for Viral Diagnostics and Therapy Pharmacol. Rev. (IF 21.1) Pub Date : 2023-07-01 Garima Sharma, Srijan Chatterjee, Chiranjib Chakraborty, Jin-Chul Kim, Martin Michel
-
Review of Natural Language Processing in Pharmacology Pharmacol. Rev. (IF 21.1) Pub Date : 2023-07-01 Dimitar Trajanov, Vangel Trajkovski, Makedonka Dimitrieva, Jovana Dobreva, Milos Jovanovik, Matej Klemen, Aleš Žagar, Marko Robnik-Šikonja, Habibeh Khoshbouei
Natural language processing (NLP) is an area of artificial intelligence that applies information technologies to process the human language, understand it to a certain degree, and use it in various applications. This area has rapidly developed in the past few years and now employs modern variants of deep neural networks to extract relevant patterns from large text corpora. The main objective of this
-
Cellular Senescence: From Mechanisms to Current Biomarkers and Senotherapies Pharmacol. Rev. (IF 21.1) Pub Date : 2023-07-01 Vasco Lucas, Cláudia Cavadas, Célia Alexandra Aveleira, Vivian Hook
-
Current and Emerging Pharmacological Targets and Treatments of Urinary Incontinence and Related Disorders Pharmacol. Rev. (IF 21.1) Pub Date : 2023-07-01 Martin C. Michel, Linda Cardozo, Christopher J. Chermansky, Francisco Cruz, Yasuhiko Igawa, Kyu-Sung Lee, Arun Sahai, Alan J. Wein, Karl-Erik Andersson, Lynette Daws
-
Extracellular Vesicle Heterogeneity and Its Impact for Regenerative Medicine Applications. Pharmacol. Rev. (IF 21.1) Pub Date : 2023-06-06 Simonides Immanuel van de Wakker,Fleur Michelle Meijers,Joost Petrus Gerardus Sluijter,Pieter Vader
Extracellular vesicles (EVs) are cell-derived membrane-enclosed particles that are involved in physiologic and pathologic processes. EVs are increasingly being studied for therapeutic applications in the field of regenerative medicine. Therapeutic application of stem cell-derived EVs has shown great potential to stimulate tissue repair. However, the exact mechanisms through which they induce this effect
-
The Myc Family and the Metastasis Suppressor NDRG1: Targeting Key Molecular Interactions with Innovative Therapeutics. Pharmacol. Rev. (IF 21.1) Pub Date : 2023-06-06 Zhao Deng,Des R Richardson
Cancer is a leading cause of death worldwide, resulting in ∼10 million deaths in 2020. Major oncogenic effectors are the Myc proto-oncogene family, which consists of three members including c-Myc, N-Myc, and L-Myc. As a pertinent example of the role of the Myc family in tumorigenesis, amplification of MYCN in childhood neuroblastoma strongly correlates with poor patient prognosis. Complexes between
-
Paradoxes of Cellular SUMOylation Regulation: A Role of Biomolecular Condensates? Pharmacol. Rev. (IF 21.1) Pub Date : 2023-05-03 Xiaodong Cheng,Wenli Yang,Wei Lin,Fang Mei
Protein SUMOylation is a major post-translational modification essential for maintaining cellular homeostasis. SUMOylation has long been associated with stress responses as a diverse array of cellular stress signals are known to trigger rapid alternations in global protein SUMOylation. In addition, while there are large families of ubiquitination enzymes, all small ubiquitin-like modifiers (SUMOs)
-
Pharmacological Regulation of Endoplasmic Reticulum Structure and Calcium Dynamics: Importance for Neurodegenerative Diseases. Pharmacol. Rev. (IF 21.1) Pub Date : 2023-05-01 Ilmari Parkkinen,Anna Their,Muhammad Yasir Asghar,Sreesha Sree,Eija Jokitalo,Mikko Airavaara
The endoplasmic reticulum (ER) is the largest organelle of the cell, composed of a continuous network of sheets and tubules, and is involved in protein, calcium (Ca2+), and lipid homeostasis. In neurons, the ER extends throughout the cell, both somal and axodendritic compartments, and is highly important for neuronal functions. A third of the proteome of a cell, secreted and membrane-bound proteins
-
Understanding the Neural Mechanisms of General Anesthesia from Interaction with Sleep–Wake State: A Decade of Discovery Pharmacol. Rev. (IF 21.1) Pub Date : 2023-05-01 Wei-Wei Bao, Shan Jiang, Wei-Min Qu, Wen-Xian Li, Chang-Hong Miao, Zhi-Li Huang, Lynette Daws
The development of cutting-edge techniques to study specific brain regions and neural circuits that regulate sleep–wake brain states and general anesthesia (GA), has increased our understanding of these states that exhibit similar neurophysiologic traits. This review summarizes current knowledge focusing on cell subtypes and neural circuits that control wakefulness, rapid eye movement (REM) sleep,
-
Sulfotransferase 2B1b, Sterol Sulfonation, and Disease Pharmacol. Rev. (IF 21.1) Pub Date : 2023-05-01 Ian Cook, Thomas S. Leyh, Stephen Alexander
-
Pharmacological Inhibition of the NLRP3 Inflammasome: Structure, Molecular Activation, and Inhibitor-NLRP3 Interaction Pharmacol. Rev. (IF 21.1) Pub Date : 2023-05-01 Qiang Ma, John Schuetz
-
Time to Change: A Systems Pharmacology Approach to Disentangle Mechanisms of Drug-Induced Mitochondrial Toxicity Pharmacol. Rev. (IF 21.1) Pub Date : 2023-05-01 Charlotte A. Hoogstraten, Jonathan J. Lyon, Jan A.M. Smeitink, Frans G.M. Russel, Tom J.J. Schirris, John Schuetz
-
Turn On, Tune In, Turnover! Target Biology Impacts In Vivo Potency, Efficacy, and Clearance Pharmacol. Rev. (IF 21.1) Pub Date : 2023-05-01 Johan Gabrielsson, Stephan Hjorth, Paul Insel
-
G Protein-Coupled Receptor Pharmacology—Insights from Mass Spectrometry Pharmacol. Rev. (IF 21.1) Pub Date : 2023-05-01 Hsin-Yung Yen, Ali Jazayeri, Carol V. Robinson, Gunnar Schulte
-
β-Arrestins: Structure, Function, Physiology, and Pharmacological Perspectives. Pharmacol. Rev. (IF 21.1) Pub Date : 2023-04-07 Jürgen Wess,Antwi-Boasiako Oteng,Osvaldo Rivera-Gonzalez,Eugenia V Gurevich,Vsevolod V Gurevich
The two β-arrestins, β-arrestin-1 and -2 (systematic names: arrestin-2 and -3, respectively), are multifunctional intracellular proteins that regulate the activity of a very large number of cellular signaling pathways and physiologic functions. The two proteins were discovered for their ability to disrupt signaling via G protein-coupled receptors (GPCRs) via binding to the activated receptors. However
-
ABCB1 and ABCG2 Regulation at the Blood-Brain Barrier: Potential New Targets to Improve Brain Drug Delivery. Pharmacol. Rev. (IF 21.1) Pub Date : 2023-03-27 Julia A Schulz,Anika M S Hartz,Björn Bauer
The drug efflux transporters ABCB1 and ABCG2 at the blood-brain barrier limit the delivery of drugs into the brain. Strategies to overcome ABCB1/ABCG2 have been largely unsuccessful, which poses a tremendous clinical problem to successfully treat central nervous system (CNS) diseases. Understanding basic transporter biology, including intracellular regulation mechanisms that control these transporters
-
Pharmacology of Heparin and Related Drugs: An Update Pharmacol. Rev. (IF 21.1) Pub Date : 2023-03-01 John Hogwood, Barbara Mulloy, Rebeca Lever, Elaine Gray, Clive P. Page, Lynette Daws
-
Targeting Persistent Changes in Neuroimmune and Epigenetic Signaling in Adolescent Drinking to Treat Alcohol Use Disorder in Adulthood Pharmacol. Rev. (IF 21.1) Pub Date : 2023-03-01 Fulton T. Crews, Leon G. Coleman, Victoria A. Macht, Ryan P. Vetreno, Robert Dantzer
-
Newly Developed Targeted Therapies Against the Androgen Receptor in Triple-Negative Breast Cancer: A Review Pharmacol. Rev. (IF 21.1) Pub Date : 2023-03-01 Edris Choupani, Mohammad Mahmoudi Gomari, Saeed Zanganeh, Sherko Nasseri, Kaveh Haji-allahverdipoor, Neda Rostami, Yaeren Hernandez, Safa Najafi, Neda Saraygord-Afshari, Arshad Hosseini, Michael Gottesman
-
Molecular Tweezers: Supramolecular Hosts with Broad-Spectrum Biological Applications Pharmacol. Rev. (IF 21.1) Pub Date : 2023-03-01 Hedieh Shahpasand-Kroner, Ibrar Siddique, Ravinder Malik, Gabriel R. Linares, Magdalena I. Ivanova, Justin Ichida, Tatjana Weil, Jan Münch, Elsa Sanchez-Garcia, Frank-Gerrit Klärner, Thomas Schrader, Gal Bitan, Habibeh Khoshbouei
Lysine-selective molecular tweezers (MTs) are supramolecular host molecules displaying a remarkably broad spectrum of biologic activities. MTs act as inhibitors of the self-assembly and toxicity of amyloidogenic proteins using a unique mechanism. They destroy viral membranes and inhibit infection by enveloped viruses, such as HIV-1 and SARS-CoV-2, by mechanisms unrelated to their action on protein
-
Pharmacological Targeting of Mitochondria in Diabetic Kidney Disease Pharmacol. Rev. (IF 21.1) Pub Date : 2023-02-13 Cleveland, K. H., Schnellmann, R. G.
Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease (ESRD) in the United States and many other countries. DKD occurs through a variety of pathogenic processes that are in part driven by hyperglycemia and glomerular hypertension, leading to gradual loss of kidney function and eventually progressing to ESRD. In type 2 diabetes, chronic hyperglycemia and glomerular hyperfiltration
-
Sex/Gender Differences in the Time-Course for the Development of Substance Use Disorder: A Focus on the Telescoping Effect Pharmacol. Rev. (IF 21.1) Pub Date : 2023-03-01 Eleanor Blair Towers, Ivy L. Williams, Emaan I. Qillawala, Emilie F. Rissman, Wendy J. Lynch, Michael Nader
-
Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning Pharmacol. Rev. (IF 21.1) Pub Date : 2023-01-01 Péter Ferdinandy, Ioanna Andreadou, Gary F. Baxter, Hans Erik Bøtker, Sean M. Davidson, Dobromir Dobrev, Bernard J. Gersh, Gerd Heusch, Sandrine Lecour, Marisol Ruiz-Meana, Coert J. Zuurbier, Derek J. Hausenloy, Rainer Schulz, Finn Olav Levy
-
Dopamine, Immunity, and Disease Pharmacol. Rev. (IF 21.1) Pub Date : 2023-01-01 Breana Channer, Stephanie M. Matt, Emily A. Nickoloff-Bybel, Vasiliki Pappa, Yash Agarwal, Jason Wickman, Peter J. Gaskill, Habibeh Khoshbouei
-
Pharmacological Modulation of the Crosstalk between Aberrant Janus Kinase Signaling and Epigenetic Modifiers of the Histone Deacetylase Family to Treat Cancer Pharmacol. Rev. (IF 21.1) Pub Date : 2023-01-01 Al-Hassan M. Mustafa, Oliver H. Krämer, Lynette Daws
-
Elucidating the Interactome of G Protein-Coupled Receptors and Receptor Activity-Modifying Proteins Pharmacol. Rev. (IF 21.1) Pub Date : 2023-01-01 Ilana B. Kotliar, Emily Lorenzen, Jochen M. Schwenk, Debbie L. Hay, Thomas P. Sakmar, Gunnar Schulte
-
Pharmacological Reviews Announces Inaugural Social Media Ambassadors. Pharmacol. Rev. (IF 21.1) Pub Date : 2022-10-01 Lynette C Daws
-
Animal Behavior in Psychedelic Research Pharmacol. Rev. (IF 21.1) Pub Date : 2022-10-01 Anna U. Odland, Jesper L. Kristensen, Jesper T. Andreasen, Lynette Daws
-
Opportunities for Nitric Oxide in Potentiating Cancer Immunotherapy Pharmacol. Rev. (IF 21.1) Pub Date : 2022-10-01 Jihoon Kim, Susan N. Thomas, Martin Michel
-
Looking Under the Lamppost: The Search for New Cancer Targets in the Human Kinome Pharmacol. Rev. (IF 21.1) Pub Date : 2022-10-01 Mireia Sueca-Comes, Elena Cristina Rusu, Anna M. Grabowska, David O. Bates, Stephen Alexander
-
The Angiotensin AT2Receptor: From a Binding Site to a Novel Therapeutic Target Pharmacol. Rev. (IF 21.1) Pub Date : 2022-10-01 U. Muscha Steckelings, Robert E. Widdop, Edward D. Sturrock, Lizelle Lubbe, Tahir Hussain, Elena Kaschina, Thomas Unger, Anders Hallberg, Robert M. Carey, Colin Sumners, Rhian Touyz